[
  {
    "ts": null,
    "headline": "Jefferies backs IQVIA and Charles River, cuts ICON on customer losses",
    "summary": "Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.",
    "url": "https://finnhub.io/api/news?id=1d4f0e065bc8367d72e0ee4d70dadac99f76cc9a7321420ef0f78f2a01d090cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757437871,
      "headline": "Jefferies backs IQVIA and Charles River, cuts ICON on customer losses",
      "id": 136690482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Investing.com -- Jefferies changes rating on major contract research organizations, upgrading IQVIA Holdings and Charles River Laboratories to Buy while cutting ICON to Hold. Contract research organizations (CROs) provide outsourced clinical trial and drug development services to pharmaceutical and biotech firms.",
      "url": "https://finnhub.io/api/news?id=1d4f0e065bc8367d72e0ee4d70dadac99f76cc9a7321420ef0f78f2a01d090cb"
    }
  },
  {
    "ts": null,
    "headline": "Evaluating Charles River Laboratories (CRL) Valuation Following New Cell Therapy Tech Integration",
    "summary": "Charles River Laboratories International (CRL) has turned heads with its latest move, announcing the integration of Akadeum Life Sciences’ GMP-grade Human T Cell Leukopak Isolation Kit into its Cell Therapy Flex Program. This partnership centers on Akadeum’s Microbubble technology, which promises to improve cell viability and simplify the cell isolation process for developers. For investors, this step signals an intention by Charles River to further establish itself as a player in the...",
    "url": "https://finnhub.io/api/news?id=7c4a7a1ebe735d3433237ed7449af0e34e31ef10897edede740b031b2db26717",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757425065,
      "headline": "Evaluating Charles River Laboratories (CRL) Valuation Following New Cell Therapy Tech Integration",
      "id": 136691139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River Laboratories International (CRL) has turned heads with its latest move, announcing the integration of Akadeum Life Sciences’ GMP-grade Human T Cell Leukopak Isolation Kit into its Cell Therapy Flex Program. This partnership centers on Akadeum’s Microbubble technology, which promises to improve cell viability and simplify the cell isolation process for developers. For investors, this step signals an intention by Charles River to further establish itself as a player in the...",
      "url": "https://finnhub.io/api/news?id=7c4a7a1ebe735d3433237ed7449af0e34e31ef10897edede740b031b2db26717"
    }
  },
  {
    "ts": null,
    "headline": "Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
    "summary": "Get insights from Charles River Labsâ CEO at Morgan Stanleyâs 2025 Global Healthcare",
    "url": "https://finnhub.io/api/news?id=47b76a7aaf821a43bdd1e1db15d142fe38e5f8ea8c26c6c29a1ecdb85919ad93",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757423384,
      "headline": "Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
      "id": 136678172,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "Get insights from Charles River Labsâ CEO at Morgan Stanleyâs 2025 Global Healthcare",
      "url": "https://finnhub.io/api/news?id=47b76a7aaf821a43bdd1e1db15d142fe38e5f8ea8c26c6c29a1ecdb85919ad93"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks Worth Your Attention and 1 We Brush Off",
    "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
    "url": "https://finnhub.io/api/news?id=1f197b5c4a555d9bea0788937ac28ae3f5ed29e7c288717ccb27fb0f50766f32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757396345,
      "headline": "2 Cash-Producing Stocks Worth Your Attention and 1 We Brush Off",
      "id": 136690027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
      "url": "https://finnhub.io/api/news?id=1f197b5c4a555d9bea0788937ac28ae3f5ed29e7c288717ccb27fb0f50766f32"
    }
  }
]